Publications by authors named "Deborah A Robins"

Claim this Profile
O
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
Julio Rosenstock, Deborah A Robins, Kevin L Duffin, Jonathan M Wilson, Yanzhu Lin

Diabetes Obes Metab· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
Raj Vuppalanchi, Rohit Loomba, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins

Aliment Pharmacol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Rohit Loomba, Mark L Hartman, Eric J Lawitz, Raj Vuppalanchi, Jérôme Boursier, Deborah A Robins

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist.
Olivier Benichou, Tamer Coskun, Malgorzata D Gonciarz, Parag Garhyan, Andrew C Adams, Deborah A Robins

Cell Metab· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Jonathan M Wilson, Yanzhu Lin, M Jane Luo, Gary Considine, Amy L Cox, Deborah A Robins

Diabetes Obes Metab· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Melissa K Thomas, Amir Nikooienejad, Ross Bray, Xuewei Cui, Jonathan Wilson, Deborah A Robins

J Clin Endocrinol Metab· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins, William C Roell, Jeffrey S Riesmeyer

Diabetes Obes Metab· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Deborah A Robins

Diabetes Obes Metab· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins

Diabetes Care· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
Christopher P Recknor, Robert R Recker, Charles T Benson, Deborah A Robins, Alan Y Chiang

J Bone Miner Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Robert R Recker, Charles T Benson, Toshio Matsumoto, Michael A Bolognese, Deborah A Robins

J Bone Miner Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teriparatide: A bone formation treatment for osteoporosis.
Erik F Eriksen, Deborah A Robins

Drugs Today (Barc)· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis